ea0022p391 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010
Hantel Constanze
, Franzev Roman
, Ozimek Alexandra
, Mussack Thomas
, Beuschlein Felix
Vascular disrupting agents (VDAs) differ from angiogenesis inhibitors by attacking established tumor blood vessels rather than preventing growth of new ones. We investigated effects of the tumor-VDA ASA404 against neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs) and adrenocortical carcinoma (ACC) 24 h after treatment of BON and NCIh295 tumor bearing mice with ASA404 (A), paclitaxel (P) or the combined administration (A+P). A significant decrease in cell pr...